^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    B Cell Non-Hodgkin Lymphoma

    3d
    A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R B-Cell NHL) (clinicaltrials.gov)
    P1, N=19, Active, not recruiting, Janssen Research & Development, LLC | Trial primary completion date: Jan 2026 --> Sep 2026
    Trial primary completion date
    |
    JNJ-8543 • rezetamig (JNJ-8780)
    3d
    A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (clinicaltrials.gov)
    P1, N=170, Recruiting, Janssen Research & Development, LLC | Trial completion date: Oct 2028 --> Feb 2029
    Trial completion date • First-in-human
    4d
    Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial) (clinicaltrials.gov)
    P2, N=42, Recruiting, Sun Yat-sen University | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial primary completion date
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Xpovio (selinexor)
    4d
    Long-term follow-up demonstrates the curative potential of dual CD19/CD22 CAR-T-cell therapy alone or combined with autologous stem cell transplantation in TP53-altered relapsed/refractory B-cell non-Hodgkin lymphoma. (PubMed, Signal Transduct Target Ther)
    Multivariate analysis identified treatment options and the presence of bulky disease as independent adverse prognostic factors for OS and PFS. These findings suggest that dual-target CD19/CD22 CAR-T-cell therapy, particularly when integrated with ASCT, may mitigate the adverse prognostic influence of TP53 alterations, offering sustained clinical benefit with manageable long-term toxicity in r/r aggressive B-NHL.
    Journal
    |
    TP53 (Tumor protein P53) • CD22 (CD22 Molecule)
    5d
    Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma (clinicaltrials.gov)
    P1, N=12, Completed, Institute of Hematology & Blood Diseases Hospital, China | Unknown status --> Completed
    Trial completion
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CD20 negative
    |
    cyclophosphamide • BZ019
    6d
    Discovery of BMS-986458, a Potent and Selective B-Cell Lymphoma 6 Protein Ligand-Directed Degrader, for the Treatment of B-Cell Non-Hodgkin Lymphoma. (PubMed, J Med Chem)
    Oral administration of BMS-986458 results in dose-dependent pharmacokinetics, pharmacodynamics, and significant antitumor efficacy in mouse models of lymphoma. A potential first-in-class agent, BMS-986458, is currently being evaluated in a phase 1/2 clinical trial (NCT06090539) for patients with relapsed/refractory NHL.
    Journal
    |
    BCL6 (B-cell CLL/lymphoma 6) • IKZF1 (IKAROS Family Zinc Finger 1) • CRBN (Cereblon) • GSPT1 (G1 To S Phase Transition 1) • SALL4 (Spalt Like Transcription Factor 4)
    6d
    ARV-393-101: A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma. (clinicaltrials.gov)
    P1, N=255, Recruiting, Arvinas Inc. | N=112 --> 255 | Trial completion date: Dec 2025 --> Mar 2028 | Trial primary completion date: Dec 2025 --> Mar 2028
    Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    |
    Columvi (glofitamab-gxbm)
    7d
    A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients With B-cell Lymphoproliferative Disorders (clinicaltrials.gov)
    P1/2, N=58, Completed, National Research Center for Hematology, Russia | Recruiting --> Completed | Trial completion date: Mar 2026 --> Nov 2025
    Trial completion • Trial completion date • IO biomarker
    |
    TP53 (Tumor protein P53) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • BCL6 (B-cell CLL/lymphoma 6)
    |
    TP53 mutation
    7d
    Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients (clinicaltrials.gov)
    P3, N=482, Completed, Gustave Roussy, Cancer Campus, Grand Paris | Unknown status --> Completed
    Trial completion
    |
    LDH elevation
    |
    Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • vincristine
    10d
    NCI-2018-02699: Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov)
    P2, N=30, Active, not recruiting, David Bond, MD | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Opdivo (nivolumab) • Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • Truxima (rituximab-abbs)
    11d
    Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003) (clinicaltrials.gov)
    P1/2, N=137, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
    Trial completion
    |
    Keytruda (pembrolizumab) • favezelimab (MK-4280)
    11d
    iMATRIX GLO: A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=65, Recruiting, Hoffmann-La Roche | Trial completion date: Sep 2029 --> Nov 2032 | Trial primary completion date: May 2029 --> Nov 2029
    Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD4 (CD4 Molecule)
    |
    carboplatin • Rituxan (rituximab) • Gazyva (obinutuzumab) • ifosfamide • etoposide IV • Actemra IV (tocilizumab) • Columvi (glofitamab-gxbm)